Actively Recruiting
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
Led by University of Minnesota · Updated on 2025-10-31
30
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
CONDITIONS
Official Title
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult (18-70 year old) kidney transplant recipients
- Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients stable on belatacept immunosuppression at initial Cytogam infusion
- CMV Ig seronegative recipient who received a CMV Ig seropositive donor kidney
- EBV IgG positive
You will not qualify if you...
- Pregnant people
- Subjects unwilling to sign consent and complete follow-up visits
- Subjects with IgA immunodeficiency
- Subjects receiving IgG therapy or who received IgG therapy within two months before enrollment
- Patients who do not speak English and require a translator and translated consent materials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
Research Team
E
Elise Reed
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here